证券研究报告·公司点评报告·医疗服务 2025 年中报点评：屈光客单提升，关注新术 式推广、组织变革、海外发展 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 20,367 | 20,983 | 23,579 | 26,302 | 29,124 | | 同比（%） | 26.43 | 3.02 | 12.37 | 11.55 | 10.73 | | 归母净利润（百万元） | 3,359 | 3,556 | 4,098 | 4,680 | 5,350 | | 同比（%） | 33.07 | 5.87 | 15.25 | 14.19 | 14.32 | | EPS-最新摊薄（元/股） | 0.36 | 0.38 | 0.44 | 0.50 | 0.57 | | P/E（现价&最新摊薄） | 36.84 | 34.80 | 30.19 | 26.44 | 23.13 | [Table_Tag] [Table_Summa ...

9月1日尾盘，医疗再度发力，A股最大医疗ETF（512170）最高涨幅升至2．58%报0．397元，突破去 年9·24行情高点0．396元，创2023年12月15日以来新高！ 风险提示：医疗 ETF 及其联接基金被动跟踪中证医疗指数，该指数基日为 2004.12.31 ，发布于 2014.10.31 。药 ETF 及其联接基金被动跟踪中证制药指数，该指数基日为 2011.12.30 ，发布日期为 2013.7.15 。 中 证 医 疗 指 数 2020 年 至 2024 年 的 分 年 度 业 绩 分 别 为 79.67% 、 -14.71% 、 -25.1% 、 -24.25% 、 -17.16% ，指数成份股构成根据该指数编制规则适时调整，其回 测历史业绩不预示指数未来表现。文中指数成份股仅作展示，个股描述不作为任何形式的投资建议，也 不代表管理人旗下任何基金的持仓信息和交易动向。基金管理人评估的医疗 ETF 、药 ETF 的风险等级为 R3- 中风险，适宜平衡型（ C3 ）及以上投资者，医疗 ETF 联接基金的风险等级是 R4- 中高风险，适宜积极 型（ C4 ）及以上投资者，适当性匹配意见请以销售机构 ...

9月1日午后，医疗继续向上，CXO巨头药明康德大涨超7%居首，千亿龙头联影医疗大涨超6%，惠泰医 疗、三博脑科等大幅跟涨。 A股最大医疗ETF（512170）迎来重要时刻，午后涨超2%，场内价格上探0．396元，刷新年内新高的 同时，触及去年9·24行情高点！ 场内交投尤为火热，截至发稿，医疗ETF（512170）成交额超10．4亿元，已超上日全天成交额。 从板块机会来看，医疗年内持续修复，医疗ETF（512170）标的指数中证医疗年初至今涨幅超20%，但 相对强势板块安全边际或仍高，且较其自身在2021年创下的历史高点仍有近60%的差距，牛市补涨空间 或巨大。 估值角度，此前连续多年的调整充分消化医疗板块估值，医疗ETF（512170）标的指数中证医疗最新PE 估值约为36倍，仍低于近10年逾60%时间区间，配置性价比相对突出。 A股走牛趋势下，估值合理的低位赛道有望迎来补涨机会，值得重点关注。 把握牛市补涨机遇，仍在低位的医疗板块值得重点关注！配置工具认准A股最大医疗ETF（512170）及 其联接基金（012323）。聚焦"医疗器械（52%）+医疗服务（40%）"，与AI医疗高相关，覆盖6只CXO 龙头 ...

Core Viewpoint - Fosun International (00656.HK) held its 2025 mid-year performance briefing on August 29, 2025, revealing several subsidiaries with potential for IPOs, indicating a strong growth trajectory and diversification strategy [2]. Group 1: Insurance Sector - Fidelidade, a leading global insurance company in Portugal, reported a premium income of €3.27 billion (approximately ¥27.24 billion) and a net profit of €133 million (approximately ¥1.11 billion) for the first half of 2025 [4]. - Fosun United Health Insurance generated a premium income of ¥3.64 billion and a net profit of ¥33 million in the same period [6]. - Peak Reinsurance reported a premium income of $1.06 billion (approximately ¥7.58 billion) and a net profit of $89 million (approximately ¥636 million) [6]. Group 2: Healthcare Sector - Fosun Health, a subsidiary of Fosun Pharma, operates 19 medical institutions with a total of 6,600 beds, aiming to create a leading healthcare technology group in Asia [7]. - Fosun Health's revenue for the first half of 2025 was ¥3.589 billion, up from ¥2.96 billion in the previous year [8]. - Luz Saúde, a leading private healthcare provider in Portugal, reported a revenue of €399 million (approximately ¥3.32 billion) and a net profit of €24 million (approximately ¥199.92 million) [15][16]. Group 3: Leisure and Tourism Sector - Atlantis Sanya, a comprehensive marine-themed resort, generated a revenue of ¥760 million in the first half of 2025, down from ¥866 million in the same period last year [10][11]. - ClubMed, a global leader in all-inclusive high-end vacations, reported a revenue of ¥9.253 billion, an increase of 3.8% year-on-year, with an operating profit of ¥1.274 billion, up 11% [17]. Group 4: Jewelry and Fashion Sector - Yuyuan Jewelry & Fashion, focusing on wholesale and retail of gold and jewelry, reported a revenue of ¥12.8 billion, down from ¥20.47 billion in the previous year [12]. Group 5: Sports Sector - Fosun Sports, involved in the operation and development of sports-related industries, reported a revenue of ¥1.02 billion, up from ¥980 million, with a net profit of approximately ¥50 million [13]. Group 6: Elderly Care Sector - Fosun Elderly Care focuses on providing health services and products for middle-class families post-retirement, with investments in nearly ten cities and over 11,000 beds secured [19]. - The revenue for Fosun Elderly Care in the first half of 2025 was ¥401 million, an increase from ¥290 million in the previous year [20].

Core Viewpoint - Neusoft Ruixin Technology Group has demonstrated significant progress in its strategic transformation, achieving a total revenue of RMB 925 million and a profit of RMB 204 million for the period ending June 30, 2025, highlighting the effectiveness of its "education, medical care, and elderly care" strategy [1][2] Financial Performance - The company reported total revenue of RMB 925 million, with a gross profit of RMB 400 million and a net profit of RMB 204 million during the reporting period [2] - The education segment generated approximately RMB 780 million, while the medical and elderly care services contributed RMB 49.7 million, increasing its share of total revenue from 0.7% to 5.4% [2][3] Strategic Transformation - Neusoft Ruixin's "education, medical care, and elderly care" strategy has begun to yield results, particularly in the elderly care sector, which is now a significant part of the company's operations [1][4] - The company has integrated its resources across education, healthcare, and technology to create a comprehensive service system that addresses the needs of different life stages [4] Operational Highlights - The company's medical entities, such as the Ruikang Cardiovascular Hospital and Ruikang Dental Hospital, have seen substantial increases in patient volume, with outpatient and emergency visits exceeding 28,000 and inpatient surgeries surpassing 5,800, marking a 34% increase compared to the previous year [3] - The occupancy rate of the Ruikang Home for the Elderly has exceeded 88%, with 92% of residents being over 80 years old, indicating strong market acceptance of its high-quality services [3] Educational Initiatives - Neusoft Ruixin's educational institutions have continued to grow, with a total enrollment of 58,000 students across three IT application-oriented universities, reflecting a 1.8% increase year-on-year [4] - The Neusoft Phoenix Academy aims to enhance the lives of the elderly through education, leveraging resources from the company's universities to create a unique intergenerational learning environment [5] Market Focus - The company is targeting the rapidly growing silver economy, with over 310 million people aged 60 and above in China by the end of 2024, positioning itself to capture this significant market opportunity [6] - Neusoft Ruixin plans to develop a "city-level smart elderly care platform" to integrate various elderly care services, aiming to transform traditional service models into more intelligent and personalized solutions [6][7] Future Plans - The "Shengqing Kangyang" smart elderly care platform launched in Shenyang has already aggregated over 780 quality service providers, with plans to expand to 10 cities and serve 2,000 elderly care institutions and 12 million elderly individuals by 2025 [7] - The company aims to leverage technology to enhance its educational and healthcare ecosystems, contributing to the high-quality development of China's silver economy [7]

Group 1 - The Hang Seng Index rose by 1.77%, gaining 442 points to reach 25,520 points, while the Hang Seng Tech Index also increased by 1.77%, with early trading volume at HKD 235 billion [1] - Alibaba's stock surged over 17% post-earnings, driven by better-than-expected growth in its cloud business and capital expenditures [1] - The Hang Seng Biotechnology Index continued to rise by 4%, with Ark Health (06086) up 11%, MicroPort Medical (00853) up 10%, and Innovent Biologics up 9% [1] Group 2 - Jihai Resources (02489) saw its stock increase by over 13% after reporting nearly a 10% year-on-year increase in net profit, positioning it as the third-largest gold mining company in Shandong [2] - AsiaInfo Technologies (01675) rose over 6% following a long-term strategic partnership with Alibaba Cloud, with expectations of improved annual profits [3] - Huajian Medical (01931) surged over 13% after announcing a plan to acquire 20.31% of Guofu Quantum for over HKD 3.1 billion, continuing to promote the RWA ecosystem [3] - Helen's (09869) stock increased by over 12%, with a net profit margin rising to 17.8% and total store count reaching 583 [3] - Beihai Kangcheng-B (01228) rose over 15% after turning a profit in the first half of the year and forming a strategic partnership with Baiyang Pharmaceutical [3] - Gacos-B (01167) surged over 20% after receiving approval for the listing of Goleirese, with mid-term revenue increasing to HKD 45.7 million [3] Group 3 - Chaoju Eye Hospital (02219) fell by 13%, reporting a 16.72% year-on-year decrease in net profit to HKD 114 million [4] - Evergrande Property (06666) dropped 4.4% in early trading, with a 5.6% decline in net profit for the first half of the year, citing pessimistic economic benefits from Evergrande Group [4] - Yangtze Optical Fibre and Cable (06869) fell over 4% post-earnings, reporting revenue growth without profit increase, with a 50% year-on-year drop in second-quarter net profit [4]

Investment Rating - The report maintains a "Buy" rating for the company [7][8]. Core Views - The company's revenue for 1H25 increased by 9.5% year-on-year to 1.49 billion RMB, while net profit rose by 41.6% to 150 million RMB, indicating strong performance driven by robust offline demand [1][7]. - The management has adjusted the 2025 revenue growth forecast to 10%-15% from the previous 25%, citing changes in the macro environment [1][7]. - The company is expected to return to a revenue growth rate of over 20% in 2026 [1]. Financial Summary - For FY25E, the company is projected to achieve sales revenue of 3.445 billion RMB, reflecting a year-on-year growth of 14.0% [2][8]. - Adjusted net profit for FY25E is estimated at 460 million RMB, with a growth rate of 15.0% [2][8]. - The adjusted earnings per share (EPS) for FY25E is forecasted to be 1.95 RMB [2][8]. Price Target and Valuation - The target price is set at 48.28 HKD, down from a previous target of 52.75 HKD, representing a potential upside of 48.6% from the current stock price of 32.50 HKD [3][7]. - The discounted cash flow (DCF) valuation indicates a per-share value of 48.28 HKD, based on a weighted average cost of capital (WACC) of 10.2% and a perpetual growth rate of 3.0% [10][11]. Shareholder Structure - The largest shareholder is Tu Zhiliang, holding 34.2% of the shares, followed by Ruiyuan Fund with 8.0% [4]. Stock Performance - The stock has shown a decline in absolute returns over the past month (-8.2%) and three months (-11.6%) [5]. Business Development - The company opened 7 new stores in 1H25, bringing the total to 83, and plans to add approximately 15 more stores in 2025 [7]. - The number of doctors in the network increased by 1,501 in 1H25, with a 23.5% year-on-year growth in offline doctors [7]. AI Initiatives - The company has launched AI initiatives, including the first "Famous Doctor AI Avatar," which is expected to generate significant revenue in the future [7]. Shareholder Returns - In 1H25, the company repurchased shares worth 84.69 million HKD, equivalent to 50% of net profit, and declared a mid-term dividend of 75.77 million RMB, also 50% of net profit [7].

Core Viewpoint - Huajian Medical (01931) has seen a significant stock increase of over 13% following the announcement of a conditional agreement to acquire a 20.31% stake in Guofu Quantum for approximately HKD 3.142 billion, which will be paid through the issuance of shares. This acquisition aims to enhance capital synergy and establish an innovative cooperative network to support the globalization of Chinese assets [1][2]. Group 1 - Huajian Medical's stock rose by 13.31% to HKD 10.98, with a trading volume of HKD 45.6534 million [1]. - The acquisition of Guofu Quantum will make Huajian Medical the major shareholder, aiming to strengthen capital collaboration and broaden institutional cooperation [1]. - The company has launched several strategic initiatives since late July, including the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2]. Group 2 - Huajian Medical's U.S. subsidiary is pursuing a stablecoin license, and the company has partnered with BGI's Huada Gongying to establish the world's first "innovative drug intellectual property tokenization fund" [2]. - The company announced the initiation of a "global enhanced Ethereum (ETH) treasury" strategy and completed a compliant purchase of HKD 149 million in ETH [2]. - Huajian Medical is seeking shareholder approval for a HKD 3 billion ETH purchase authorization to support the ecosystem construction of the medical innovative drug RWA trading platform [2].

Group 1 - Huajian Medical (01931) shares rose over 13%, reaching 10.98 HKD with a trading volume of 45.65 million HKD [1] - The company announced a conditional agreement to acquire 20.31% of Guofu Quantum's shares for approximately 3.142 billion HKD, to be paid through the issuance of consideration shares [1] - This acquisition aims to enhance capital synergy, promote the implementation of RWA ecosystem, and build an innovative cooperation network to support the globalization of Chinese assets [1] Group 2 - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [2] - The company is pursuing a stablecoin license for its U.S. subsidiary and has partnered with BGI's subsidiary to establish the world's first "innovative drug intellectual property tokenization fund" [2] - On August 8, Huajian Medical initiated the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [2] - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the RWA trading platform [2]

龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%、日振幅值达15%上榜龙虎榜1 次，买卖居前营业部中，营业部席位合计净买入6368.89万元。 济民健康再度涨停，4个交易日内录得3个涨停，累计涨幅为38.77%，累计换手率为83.75%。截至 10:12，该股今日成交量7899.94万股，成交金额9.68亿元，换手率15.04%。最新A股总市值达66.53亿 元。 证券时报·数据宝统计，两融数据来看，该股最新（8月29日）两融余额为2.10亿元，其中，融资余额 2.10亿元，较前一个交易日减少3335.79万元，环比下降13.71%，近4日累计减少6462.93万元，环比下降 23.54%。 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.08.29 | 4.35 | 22.32 | 1215.91 | | 2025.08.28 | 9.96 | 24.19 | 12589.52 | | 2025.08.27 | 9.97 | 22.20 | 11804.67 | | 2025.08 ...